Mahe Julien, Meurette Aurélie, Moreau Anne, Vercel Caroline, Jolliet Pascale
Clinical Pharmacology Department, Institute of Biology, University Hospital, Nantes, France.
Drug Des Devel Ther. 2013 Aug 7;7:723-8. doi: 10.2147/DDDT.S42138. eCollection 2013.
Interferon beta-1a is available as an immunomodulating agent for relapsing forms of multiple sclerosis. Common side effects include flu-like symptoms, asthenia, anorexia, and administration site reaction. Kidney disorders are rarely reported. In this study we describe the case of a woman who has been undergoing treatment with interferon beta-1a for multiple sclerosis for 5 years. She developed a hemolytic-uremic syndrome with intravascular hemolysis in a context of severe hypertension. A kidney biopsy showed a thrombotic microangiopathy. This observation highlights an uncommon side effect of long-term interferon beta-1a therapy. Pathophysiological mechanisms leading to this complication might be explained by the antiangiogenic activity of interferon.
β-1a干扰素作为一种免疫调节剂,可用于复发型多发性硬化症的治疗。常见副作用包括流感样症状、乏力、厌食以及注射部位反应。肾脏疾病鲜有报道。在本研究中,我们描述了一名女性患者的病例,她接受β-1a干扰素治疗多发性硬化症已达5年。在严重高血压的情况下,她出现了伴有血管内溶血的溶血尿毒综合征。肾脏活检显示为血栓性微血管病。这一观察结果凸显了长期使用β-1a干扰素治疗的一种罕见副作用。导致这种并发症的病理生理机制可能可用干扰素的抗血管生成活性来解释。